Managing Partner, VRS (Valuation & Research Specialists)

VRS (Valuation & Research Specialists)

Financial analyst specializing on corporate valuation. Long-term experience in analyzing and valuing listed and non listed companies in a wide range of business sectors in Europe, North America and internationally. Some of the sectors covered are financial services, industrials, high technology and real estate. Certified Equity Analyst by the Hellenic Capital Market Commission, Greece. Member of the Hellenic Association of Certified Securities Analysts (HACSA), Greece. Associate Member of the Chartered Institute for Securities & Investment (CISI), UK.

Specialties: Applying methods in corporate valuation, developing valuation models and writing equity research and valuation reports. Consulting services to companies with regard to their valuation drivers and potential corporate value, utilized in corporate deals such as mergers, acquisitions and sale of businesses. Specialized financial translations.

Managing Partner

Valuation & Research Specialists (VRS) is a boutique financial advisor with more than 17 years of experience in Corporate Valuation and Finance, and a diversified client base including some of the largest Companies in Greece.

Since 2002, VRS has completed more than 200 engagements in the areas of business valuation and financial analysis for more than 100 clients in a wide range of industries.

VRS has been honored to work with small and large private and publicly traded companies in Europe and overseas.

Boutique Financial Advisor

Equity Bottom-Up

Interlife General Insurance  / Equity Bottom-Up

<ul><li>Strong Insurance Revenue growth by 11.71% for 2023 (FH 2023: EUR 42,305,397 vs FH 2022: EUR 37,869,728) and robust Investments and Miscellaneous Income growth by 176.62% for 2023 (FH 2023: EUR 12,189,980 vs FH 2022: EUR (15,910,269)) were the key factors for INTERLIFE to return to profitability, posting an EBIT of 13,535,165 EUR, 223.83% increase compared to FY 2022 and an EPS at 0.591 EUR, +221.38% from the FH 2022.</li><li>INTERLIFE holds twice the capital needed for severe disasters, with a Solvency Capital Requirement (SCR=Total eligible own funds / Solvency Capital Requirement) Ratio adequacy of 201.44%, surpassing the 180% Greek benchmark of 2022 and with a Minimum Capital Requirement (MCR= Total eligible own funds / Minimum Capital Requirement) Ratio of 707.87%.</li><li>INTERLIFE does not possess proportional contracts but reinsurance contracts that can reach up to 1 million.</li></ul>

Strong Insurance Revenue growth by 11.71% for 2023 (FH 2023: EUR 42,305,397 vs FH 2022: EUR 37,869,728) and robust Investments and Miscellaneous Income growth by 176.62% for 2023 (FH 2023: EUR 12,189,980 vs FH 2022: EUR (15,910,269)) were the key factors for INTERLIFE to return to profitability, posting an EBIT of 13,535,165 EUR, 223.83% increase compared to FY 2022 and an EPS at 0.591 EUR, +221.38% from the FH 2022.INTERLIFE holds twice the capital needed for severe disasters, with a Solvency Capital Requirement (SCR=Total eligible own funds / Solvency Capital Requirement) Ratio adequacy of 201.44%, surpassing the 180% Greek benchmark of 2022 and with a Minimum Capital Requirement (MCR= Total eligible own funds / Minimum Capital Requirement) Ratio of 707.87%.INTERLIFE does not possess proportional contracts but reinsurance contracts that can reach up to 1 million.

Interlife General Insurance Company S.a. - 6M-9M FY2023 Results Presentation